Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 31, p.4747-54 (2010)

Keywords:

2010, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Non-Small-Cell Lung, Center-Authored Paper, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, paclitaxel, Patient Selection, Proto-Oncogene Proteins, Public Health Sciences Division, Quinazolines, ras Proteins, Receptor, Epidermal Growth Factor, Research Design, Southwestern United States, Treatment Outcome, Tumor Markers, Biological

Abstract:

Randomized clinical trials failed to show a survival benefit for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors plus concurrent chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC), with preclinical data suggesting potential negative interactions. In contrast, pilot trials of the EGFR-targeted antibody, cetuximab, plus chemotherapy suggested enhanced antitumor activity. This randomized phase II trial was designed to select a cetuximab plus chemotherapy regimen for phase III evaluation.